Clinical Trial Update: Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating neoadjuvant therapy combining palbociclib, exemestane, trastuzumab, and pyrotinib in ER-positive, HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Exemestane (Exemestane)
• Palbociclib (palbociclib)
• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Guangdong Provincial People's Hospital | Conditions: Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer | Phase 2 | Status: UNKNOWN